**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners list of indications that may be commissioned for excluded drugs and devices 2021/2022 v1**

High cost drugs excluded from the 2021/2022 National Tariff are not commissioned by Mid and South Essex Clinical Commissioning Groups (CCGs) unless the drugs and indications have approval through local processes.

The table in Appendix 1 summarise the policy on the commissioning of drugs and devices. It is coded by a "traffic light" scheme as follows:

| | |
|---|---|
| **Any drug and/or indication (licensed or unlicensed use) not listed In Appendix 1 is designated as NOT COMMISSIONED** | |
| | Not commissioned. Where provider Trusts prescribe this treatment the funding responsibility lies with the provider and not the commissioner. |
| | Approved for use in line with NICE Guidance or where NICE has been converted into a locally agreed protocol. Notification or individual or group prior approval required using proforma as per contract. Clinical evidence of outcomes may be requested by CCGs (in line with local contracts). Funding will not be authorised for patients who do not meet agreed criteria. |
| | Approved for use in line with locally agreed guidance only. Prior approval, notification proformas or electronic Blueteq® forms should be completed. Indications with other minimum dataset information must be provided on back up data to invoices. |
| | NHSE commissioning responsibility. CCGs should not consider funding requests for these drugs in these indications / group of patients. For drugs or indications where NHS England is the responsible commissioner the current version of the NHS England drug list should be refered to for the commissioning position, this is located at :- https://www.england.nhs.uk/commissioning/spec-services/key-docs/ |

Please note that the enclosed information reflects the current commissioning arrangements. These arrangements are subject to change in year if commissioning responsibility for particular drugs or services change between Mid and South Essex CCGs and the NHS England and / or new local drug policies are introduced or new NICE guidance is published.

**The main reference sources used to produce this document were:**


1. National Tariff payment system 2020 2021 Annex A: The National Tariff and national prices workbook, High cost drugs and devices available at https://improvement.nhs.uk/resources/national-tariff/
2. East of England Priorities Advisory Commmittee (PAC) recommendations available at: http://www.prescqipp.info/
3. National Institute for Health and Care Excellence (NICE) Guidance available at www.nice.org.uk.
4. UKMi Prescribing Outlook 2020 available from Specialist Pharmacy Services https://www.sps.nhs.uk/articles/prescribing-outlook-2020/
5. UKMi New Drugs Online available from Specialist Pharmacy Services https://www.sps.nhs.uk/
6. Indications for NHS England drugs list v15 published April 2020 available at https://www.england.nhs.uk/commissioning/spec-services/key-docs

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| |
|---|
| **High cost drugs excluded from the 2021-22 National Tariff are not commissioned by Mid and South Essex Clinical Commissioning Groups (CCGs) unless the drugs and indications have approval through local processes.** |
| Please note that the enclosed information reflects the current commissioning arrangements. These arrangements are subject to change in year if commissioning responsibility for particular drugs or services change between Mid and South Essex CCGs and the NHS England and/or new local drug policies are introduced or new NICE guidance is published. |
| **Any drug and/or indication (licensed or unlicensed use) not listed In Appendix 1 is designated as NOT COMMISSIONED** |
| The table in Appendix 1 summarise the policy on the commissioning of drugs and devices. It is coded by a "traffic light" scheme as follows: |

| | |
|---|---|
| | Not commissioned. Where provider Trusts prescribe this treatment the funding responsibility lies with the provider and not the commissioner. |
| | Approved for use in line with NICE Guidance or where NICE has been converted into a locally agreed protocol or EoE CCG policy. Notification or individual or group prior approval required using proforma or electronic Blueteq® forms as per contract. Clinical evidence of outcomes may be requested by CCGs (in line with local contracts). Funding will not be authorised for patients who do not meet agreed criteria. |
| | Approved for use in line with locally agreed guidance only. Prior approval, notification proformas or electronic Blueteq® forms should be completed. Indications with other minimum dataset information must be provided on back up data to invoices. |
| | NHS England commissioning responsibility. CCGs should not consider funding requests for these drugs in these indications / group of patients. For drugs or indications where NHS England is the responsible commissioner the current version of the NHS England drug list should be refered to for the commissioning position, this is located at : https://www.england.nhs.uk/commissioning/spec-services/key-docs/ |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Abatacept | 10.1.3 | Cytokine modulators | Rheumatoid arthritis after failure of anti-TNF | NICE TA195, August 2010 | In line with NICE TA195. | Complete proforma (using agreed local systems) | CCG commission adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use. |
| Abatacept | 10.1.3 | Cytokine modulators | Rheumatoid Arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | NICE TA375 January 2016. (partial review of TA375, NICE ID2710. In development [GID-TA10586] | In line with NICE TA375. | Complete proforma (using agreed local systems) | CCG commission adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use. NICE TA375 replaced NICE TA280 |
| Abatacept | 10.1.3 | Cytokine modulators | Polyarticular juvenile idiopathic arthritis (2nd line only). Unlicensed use in adults. | NICE TA373 December 2015 | In line with NICE TA373. | Complete proforma (using agreed local systems) | CCG commision adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use. |
| Abatacept | 10.1.3 | Cytokine modulators | Active psoriatic arthritis after DMARDs | NICE TA568 March 2019 Terminated appraisal. | NOT COMMISSIONED | NOT COMMISSIONED | |
| Abrocitinib | | JAK inhibitor | Moderate to severe atopic dermatitis, in adults | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | UK availability 2021 |
| Actoxumab | | Monoclonal antibodies. No BNF category | Prevention of recurrence of Clostridium difficile infection | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Not licensed yet |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Adalimumab or biosimilar | 13.5.3 | Cytokine modulators | Psoriasis | NICE TA146 June 2008 | In line with NICE TA146. | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis in children NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome. |
| Adalimumab or biosimilar | 1.5.3 | Cytokine modulators | Crohn's Disease | NICE TA187 May 2010 | In line with NICE TA187 | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis in children NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome. |
| Adalimumab or biosimilar | 10.1.3 | Cytokine modulators | Psoriatic Arthritis | NICE TA199, August 2010 | In line with NICE TA199. | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis in children NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Adalimumab or biosimilar | 1.5.3 | Cytokine modulators | Moderate to severe active ulcerative colitis after the failure of conventional therapy | NICE TA329 February 2015 | In line with NICE criteria TA329 | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis in children NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome. |
| Adalimumab or biosimilar | 10.1.3 | Cytokine modulators | Rheumatoid arthritis | NICE TA375 January 2016. (partial review of TA375, NICE ID2710. In development [GID-TA10586] Expected publication date: TBC | In line with NICE criteria TA375 or TA195. | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis in children NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome. |
| Adalimumab or biosimilar | 10.1.3 | Cytokine modulators | Ankylosing spondylitis | NICE TA383 February 2016 | In line with NICE TA383. | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis in children NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Adalimumab or biosimilar | 10.1.3 | Cytokine modulators | Axial spondyloarthritis (non- radiographic) | NICE TA383 February 2016 | In line with NICE TA383 | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis in children NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome. |
| Adalimumab or biosimilar | 10.1.3 | Cytokine modulators | Polyarticular juvenile idiopathic arthritis | NICE TA373 December 2015 | In line with NICE TA373. | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis in children NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome. |
| Afamelanotide | | Skin conditions | Prevention of phototoxicity in erythropoietic protoporphyria (EPP). | NICE ID927 In development [GID-HST10009] Publications date TBC. Original FAD negative. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch TBC confirmed pending NICE appeal. Likely NHS England commissioning responsibility |
| Aflibercept | 11.8.2 | Subfoveal choroidal neovascularisation | Neovascular (wet) age-related macular degeneration. | NICE TA294, July 2013 | In line with NICE TA294. | Complete proforma (using agreed local systems) | NHSE is responsible commissioner for cancer indications. |
| Aflibercept | 11.8.2 | Subfoveal choroidal neovascularisation | Macular oedema, secondary to CRVO | NICE TA305, February 2014 | In line with NICE TA305 | Complete proforma (using agreed local systems) | NHSE is responsible commissioner for cancer indications. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Aflibercept | 11.8.2 | Subfoveal choroidal neovascularisation | Diabetic Macular Oedema | NICE TA346 July 2015 | In line with NICE TA346 | Complete proforma (using agreed local systems) | NHSE is responsible commissioner for cancer indications. |
| Aflibercept | 11.8.2 | Subfoveal choroidal neovascularisation | Macular oedema, secondary to BRVO | NICE TA409 September 2016 | In line with NICE TA409 | Complete proforma (using agreed local systems) | NHSE is responsible commissioner for cancer indications. |
| Aflibercept | 11.8.2 | Subfoveal choroidal neovascularisation | Choroidal neovascularisation | NICE TA486 November 2017 | In line with NICE TA486 | Complete proforma (using agreed local systems) | NHSE is responsible commissioner for cancer indications. |
| Alicaforsen | 1.05 | Inhibition of ICAM-1 production | Ulcerative colitis | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | |
| Alirocumab | 2.12 | Lipid-regulating drugs | Primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia. | NICE TA 393 June 2016 | In line with NICE TA393 and EoE PAC recommendations. | Complete proforma (using agreed local systems) | |
| Alirocumab | 2.12 | Lipid-regulating drugs | Cardiovascular event reduction in patients with established atherosclerotic cardiovascular disease. | No NICE guidance expected | NOT COMMISSIONED | NOT COMMISSIONED | |
| Alitretinoin | 13.5.1 | Skin conditions | Severe chronic hand eczema | NICE TA177, August 2009 | In line with NICE TA177. | Complete proforma (using agreed local systems) | Adults only. GP prescribing NOT expected. |
| Amikacin Liposomal inhalation | 5.1.4 | Aminoglycosides | Nontuberculous mycobacterial lung infection | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | NHS England responsible commissioner for use in CF |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Anakinra | 10.1.3 | Cytokine modulators | Rheumatoid arthritis | NICE TA72, November 2003 (replaced by NICE CG79, February 2010), not recommended | NOT COMMISSIONED | NOT COMMISSIONED | NHS England responsible commissioner for adult specialised autoinflammatory disease, paediatric use, Cropyrin associated periodic syndrome, Stills disease (juvenile idiopathic arthritis). |
| Andexanet alfa | | Factor Xa inhibitor antidote | Reversal of Factor Xa inhibition | NICE ID1101. In development [GID-TA10440] Publication date TBC | NOT COMMISSIONED | NOT COMMISSIONED | |
| Apremilast | 10.1.3 | Cytokine modulators | Psoriasis | NICE TA419 November 2016 | In line with NICE TA419. | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use. |
| Apremilast | 10.1.3 | Cytokine modulators | Psoriatic arthritis unresponsive to DMARDs | NICE TA433 February 2017 | In line with NICE TA433. | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use. |
| Avatrombopag | 9.1.4 | Platelet disorder drugs | Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | NICE TA626 June 2020 | In line with NICE TA626 | Complete proforma (using agreed local systems) | |
| Avatrombopag | 9.1.4 | Platelet disorder drugs | ITP first line | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch 2019. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Aztreonam Lysine nebuliser solution | 5.1.2.3 | Antibacterial drugs | Cystic Fibrosis | NHSE commissioning policy for CF | In line with NHSE Policies for CF Policy Ref: A01/P/b Dec 2014 and Policy Ref: 16001/P July 2016 | NHSE responsibility | Only excluded when given by nebulisation / inhalation. NHS England responsible commissioner for use in CF |
| Aztreonam Lysine nebuliser solution | 5.1.2.3 | Antibacterial drugs | Bronchiectasis | Bronchiectasis only in line with Local Policies | NOT COMMISSIONED | NOT COMMISSIONED | Only excluded when given by nebulisation / inhalation. NHS England responsible commissioner for use in CF |
| Baricitinib | 10.1.3 | Cytokine modulators | Moderate to severe active rheumatoid arthritis not to, or who are intolerant to one or more DMARDs. | NICE TA466 August 2017 | In line with NICE TA466. | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use. |
| Baricitinib | 10.1.4 | Cytokine modulators | Atopic dermatitis in adults. Moderate to severe. | NICE TA681 March 2021 | In line with NICE TA681 | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected. |
| Benralizumab | | Interleukin-5 receptor (IL-5R) monoclonal antibody. | COPD, moderate-to-very severe with a history of exacerbations. | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | UK launch plans uncertain. NHS England repsonsible for severe eosinophilic asthma indication NICE TA 565 |
| Bevacizumab (Avastin) | | anti VEGF monoclonal antibody | Juxtafoveal telangiecstasis | Local policy | NOT COMMISSIONED | NOT COMMISSIONED | NHSE are the responsible commissioners for cancer indications and neurofibromatosis |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Bevacizumab (Avastin) | | anti VEGF monoclonal antibody | wet aged-related macular degeneration | Local policy (PAC statement) | NOT COMMISSIONED | NOT COMMISSIONED | NHSE are the responsible commissioners for cancer indications and neurofibromatosis |
| Bevacizumab biosimilar (ONS-5010) | | Anti VEGF monoclonal antibody | Wet aged-related macular degeneration | No specific NICE guidance anticipated - would expect to follow NICE TA155 | NOT COMMISSIONED | NOT COMMISSIONED | Predicted launch date 2021 |
| Bezlotoxumab | | Human monoclonal antibody | Prevention of recurrence of Clostridium difficile infection | NICE TA601, September 2019 Terminated appraisal. | NOT COMMISSIONED | NOT COMMISSIONED | |
| Bimekizumab | | Human monoclonal antibody | Moderate to severe chronic plaque psoriasis | NICE [ID2692] Proposed [GID-TA10649] - Publication date September 2021 | NOT COMMISSIONED | NOT COMMISSIONED | |
| Deucravacitinib | | Tyrosine kinase 2 inhibtor | Moderate to severe chronic plaque psoriasis | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | UK Launch 2022 |
| Botulinum Toxin A | 4.7.4.2 | Prophylaxis of migraine | Migraine prophylaxis | NICE TA260, June 2012 | In line with NICE TA260 | Complete proforma (using agreed local systems) | GP prescribing NOT expected |
| Botulinum Toxin A (Xeomin®) | 4.9.3 | Essential tremor, chorea, tics and related disorders | Chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults | NICE TA 605, October 2019 | In line with NICE TA605 | Complete proforma (using agreed local systems) | License extension for use in children TBC - UK availability 2021 |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Botulinum Toxin A | 4.9.3 | Essential tremor, chorea, tics and related disorders | Spasticity (after stroke) where there is a dynamic spastic component (as opposed to contracture) and there are anticipated functional gains in line with Royal College of Physician guidance. | NICE ID768 - In development [GID-TAG499] - expected publication date TBC | In line with PAC recommendations | Complete proforma (using agreed local systems) | NHS England is responsible commissioner for focal spasticity in children. Treatment of spasticity in paediatric cerebral palsy is commissioned by NHSE at specialist centres only. Intravesical use in spinal injury commissioned by NHSE. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Botulinum Toxin A | 4.9.3 | Essential tremor, chorea, tics and related disorders | Chronic anal fissure, severe blepharospasm, hemifacial spasm, cervical dystonia (spasmodic torticollis) in adults, focal spasticity in adults, hyperhidrosis of the axillae, palmar or craniofacial, dysphagia caused by achalasia, Hirschsprung's disease, overactive bladder, spasticity treatment in paediatric cerebral palsy when not in specialist centres, Masseteric hypertrophy and Temporomandibular Disorders. | No NICE guidance anticipated | In line with PAC recommendations. | Complete proforma (using agreed local systems) | GP prescribing NOT expected.NHS England is responsible commissioner for focal spasticity in children. Treatment of spasticity in paediatric cerebral palsy is commissioned by NHSE at specialist centres only. Intravesical use in spinal injury commissioned by NHSE. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Botulinum Toxin A | 4.9.3 | Essential tremor, chorea, tics and related disorders | Chronic sialorrhoea in children with cerebral palsy, laryngeal dystonia (spasmodic dystonia), hydradenitis suppurative, plantar hyperhidrosis, mechanical neck disorders, correction of strabismus (squint) in paediatrics, dysphagia (causes other than achalasia), Raynaud's Disease. | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | Not commissionined in line with negative PAC recommendations. |
| Brimapitide | 12 | Protein kinase inhibitors | Acute sensorineural hearing loss (ASNHL) | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch 2023 |
| Brodalumab | 13.5.3 | Drugs affecting the immune response | Moderate to severe plaque psoriasis | NICE TA511 March 2018 | In line with NICE TA511 | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use. |
| Brolucizumab | 10.1.3 | Cytokine modulators | Wet aged-related macular degeneration | NICE TA672 February 2021 | In line with NICE TA672 | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Cannabidiol | | Cannabinoids | All indications | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | Cannabidiol with clobazam as an option for treating seizures associated with Dravet syndrome (NICE TA 614) and Lennox-Gastaut syndrome (NICE TA 615) in people aged 2 years and older commissioned by NHS England. |
| Certolizumab Pegol | 10.1.3 | Cytokine modulators | Rheumatoid Arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | NICE TA375 January 2016. (partial review of TA375, NICE ID2710. In development [GID-TA10586] Expected publication date: TBC | In line with NICE TA375 | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use. |
| Certolizumab Pegol | 10.1.3 | Cytokine modulators | Ankylosing spondylitis | NICE TA383, February 2016 | In line with NICE TA383. | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use. |
| Certolizumab Pegol | 10.1.3 | Cytokine modulators | Axial spondyloarthritis (non radiographic) | NICE TA383, February 2016 | In line with NICE TA383. | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use. |
| Certolizumab Pegol | 10.1.3 | Cytokine modulators | Rheumatoid arthritis after TNF inhibitor | NICE TA415 Oct 2016 | In line with NICE TA415 | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Certolizumab Pegol | 10.1.3 | Cytokine modulators | Active psoriatic arthritis after DMARDs | NICE TA445 May 2017 | In line with NICE TA445 | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use. |
| Certolizumab Pegol | 10.1.3 | Cytokine modulators | Moderate to severe plaque psoriasis | NICE TA574 April 2019 | In line with NICE TA574 | Complete proforma (using agreed local systems) | CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use. |
| Cobitolimod | | DNA-based immunomodulatory sequence given intracolonically | Ulcerative colitis (UC) refractory, 3rd line | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | No predicted launch date. |
| Colistimethate sodium powder for nebulisation | 5.1.7 | Antibacterial drugs | Cystic Fibrosis | NICE TA276 March 2013 | NHSE Policy -Inhaled Therapy For Adults And Children With Cystic Fibrosis Policy Ref: A01/P/b Dec 2014 | NHSE responsibility | Only excluded when given by nebulisation/inhalation. |
| Colistimethate sodium dry powder for inhalation (Colobreathe®) | 5.1.7 | Antibacterial drugs | Cystic Fibrosis | NICE TA276, March 2013. | NHSE Policy -Inhaled Therapy For Adults And Children With Cystic Fibrosis Policy Ref: A01/P/b Dec 2014 | No GP prescribing as Patient Access Scheme not available in primary care. | Only excluded when given by nebulisation/inhalation. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Colistimethate inhaled (promixin) | 5.1.7 | Antibacterial drugs | Non-cystic fibrosis (CF) related bronchiectasis - first-line in patients colonised with Pseudomonas aeruginosa | NO NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | UK availability 2021. Local policies may be in place. |
| Collagenase | 10.1.3 | Enzymes | Peyronie's disease (PsD) | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Only excluded from tariff when used in outpatients. Collagenase clostridium histolyticum (Xiapex) is no longer available in the UK. |
| Collagenase | 10.1.3 | Enzymes | Dupuytren's Contracture | NICE TA459 withdrawn | NOT COMMISSIONED | NOT COMMISSIONED | Collagenase clostridium histolyticum (Xiapex) is no longer available in the UK. |
| Deferasirox | 9.1.3 | Iron overload | Anaemia related to chronic iron overload for myelodysplastic syndrome only | PAC recommendation (not recommended) | Only in line with Local Policies | NOT COMMISSIONED | NHS England responsible commissioner for hypoplastic, haemolytic and renal anaemias - iron overload, thalassemia and sickle cell disease. NHSE routinely commissioned in combination when dual therapy required. |
| Deferiprone | 9.1.3 | Iron overload | Anaemia related to chronic iron overload for myelodysplastic syndrome only | PAC recommendation (not recommended) | Only in line with Local Policies | NOT COMMISSIONED | NHS England responsible commissioner for hypoplastic, haemolytic and renal anaemias - iron overload, thalassemia and sickle cell disease. NHSE routinely commissioned in combination when dual therapy required. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Desferrioxamine | 9.1.3 | Iron overload | Anaemia related to chronic iron overload for myelodysplastic syndrome only | PAC recommendation (not recommended) | Only in line with Local Policies | NOT COMMISSIONED | NHS England responsible commissioner for hypoplastic, haemolytic and renal anaemias - iron overload, thalassemia and sickle cell disease. NHSE routinely commissioned in combination when dual therapy required. |
| Dexamethasone intravitreal implant | 11.4.1 | Corticosteroid | Macular oedema secondary to retinal vein occlusion. | NICE TA229, July 2011. | In line with NICE TA229. | Complete proforma (using agreed local systems) | |
| Dexamethasone intravitreal implant | 11.4.1 | Corticosteroid | Diabetic Macular Oedema | NICE TA349 July 2015 | In line with NICE TA349 | Complete proforma (using agreed local systems) | |
| Dexamethasone intravitreal implant | 11.4.2 | Corticosteroid | Non-infectious uveitis (unilateral) | NICE TA460 July 2017 | In line with NICE TA460 criteria. | Complete proforma (using agreed local systems) | |
| Dexamethasone intracanalicular insert | | Corticosteroid | Occular inflammation and pain following cataract surgery | NICE ID1154 Proposed [GID-TA10198] Date: TBC | NOT COMMISSIONED | NOT COMMISSIONED | |
| Dibotermin alfa | | Bone morphogenetic protein | Acute tibia fractures | No NICE guidance anticipated. | Only in line with Local Policies (PAC policy) | Complete proforma (using agreed local systems) | NHS England responsible commissioner for complex spinal surgery NHSE policy 16063. |
| Digoxin immune fab | 2.1.1 | Poisoning | Life-threatening digoxin toxicity. | National Poisons Centre Guidelines. | Only commissioned in line with National Poison Centres guidelines. | Local Commissioner to be notified / invoiced when used. | Available on named patient basis only in hospitals. |
| Dimethyl fumarate | 13.5.2 | Preparations for psoriasis | Moderate to severe plaque psoriasis | NICE TA475 September 2017 | In line with NICE TA475 | Complete proforma (using agreed local systems) | NHS England is responsible commissioner for Multiple Sclerosis. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Dupilumab injection | 13 | Anti-interleukin -4 and -13 receptor monoclonal antibody | Atopic dermatitis, moderate-to-severe. | NICE TA534 August 2018 | In line with NICE TA534 | Complete proforma (using agreed local systems) | NHS England responsible commissioner for asthma and paediatric dermatitis indications. |
| Dupilumab injection | 13 | Anti-interleukin -4 and -13 receptor monoclonal antibody | Nasal polyposis and chronic sinusitis in adults | NICE TA648 September 2020 Terminated appraisal | NOT COMMISSIONED | NOT COMMISSIONED | Predicted launch 2020 |
| Eculizumab | 10 | Recombinant humanised monoclonal antibody. | Myasthenia Gravis (MG), generalised, refractory, in patients who are anti-acetylcholine receptor antibody-positive | NICE TA636 June 2020 Terminated appraisal | NOT COMMISSIONED | NOT COMMISSIONED | NHS England is responible commissioner for Atypical haemolytic uremic syndrome (AHUS), Paroxysmal nocturnal haemoglobinuria (PNH), organ rejection post kidney transplant, C3 glomerulopathy post transplant. |
| Eltrombopag | 9.1.4 | Platelet disorder drugs | Chronic idiopathic thrombocytopenic purpura (ITP) | NICE TA648 September 2020 | In line with NICE TA293 | Complete proforma (using agreed local systems) | GP prescribing NOT expected. NHS England are the responsible commissioner for use in paediatrics |
| Eltrombopag | 9.1.4 | Platelet disorder drugs | Thrombocytopenia in adult patients with chronic hepatitis C virus infection | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | GP prescribing NOT expected.PAC recommendations published Sept 2014. NHS England are the responsible commissioner for use in paediatrics. |
| Eltrombopag | 9.1.4 | Platelet disorder drugs | Severe aplastic anaemia (SAA) refractory immunosuppressive therapy | NICE TA382 January 2016 Terminated appraisal | NOT COMMISSIONED | NOT COMMISSIONED | NHS England are the responsible commissioner for use in paediatrics |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Eptinezumab | 4.7.4.2 | Immunomodulating drugs | Migraine prophylaxis | NICE [ID3803] Proposed [GID-TA10677] Date TBC | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch-2022 |
| Erythropoietins | 9.1.3 | Drugs used in renal anaemias | Pre-dialysis | No NICE guidance anticipated. | Only in line with Local Policies | Complete proforma (using agreed local systems) | |
| Erenumab | | Humanised monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP) | Migraine, prevention in adults. | NICE TA682 March 2021 | In line with NICE TA682 | Complete proforma (iusing agreed local systems) | CCG commission Adults only, GP prescribing NOT expected |
| Etanercept or biosimilar | 10.1.3 | Cytokine modulators | Rheumatoid Arthritis | NICE TA195 August 2010 or NICE TA375 January 2016. (partial review of TA375, NICE ID2710. In development [GID-TA10586] Expected publication date: TBC | In line with NICE criteria TA375 or TA195. | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use as per TA455 or adult TAs (TA103, TA130, TA143, TA199) |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Etanercept or biosimilar | 10.1.3 | Cytokine modulators | Ankylosing spondylitis | NICE TA383 February 2016 | In line with NICE TA383 | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use as per TA455 or adult TAs (TA103, TA130, TA143, TA199) |
| Etanercept or biosimilar | 10.1.3 | Cytokine modulators | Axial spondyloarthritis (non radiographic) | NICE TA383 February 2016 | In line with NICE TA383 | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use as per TA455 or adult TAs (TA103, TA130, TA143, TA199) |
| Etanercept or biosimilar | 10.1.3 | Cytokine modulators | Psoriatic Arthritis | NICE TA199, August 2010 | In line with NICE TA199. | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use as per TA455 or adult TAs (TA103, TA130, TA143, TA199) |
| Etanercept or biosimilar | 10.1.3 | Cytokine modulators | Psoriasis | NICE TA103, July 2006 | In line with NICE TA103. | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use as per TA455 or adult TAs (TA103, TA130, TA143, TA199) |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Etanercept or biosimilar | 10.1.3 | Cytokine modulators | Polyarticular juvenile idiopathic arthritis or Enthesitis-related JIA or Psoriatic JIA. Unlicensed use in adults. | NICE TA373 Dec 2015 | In line with NICE TA373. | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use as per TA455 or adult TAs (TA103, TA130, TA143, TA199) |
| Etrolizumab | | Monoclonal antibody | Ulcerative colitis (UC) naive to TNF inhibitors and refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment | NICE [ID3827] Proposed [GID-TA10717] Expected publication date: TBC | NOT COMMISSIONED | NOT COMMISSIONED | Predicted launch 2021. NHS England is responsible commissioner for paediatric use. |
| Etrolizumab | | Monoclonal antibody | Crohn's disease, moderate-to-severe after steroids, immunosuppressants and anti-TNF therapy | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted launch 2023. NHS England is responsible commissioner for paediatric use. |
| Evolocumab | 2.12 | PCSK9 Monoclonal Antibody Inhibitor | Hyperlipidaemia and mixed dyslipidaemia | NICE TA394, June 2016. | In line with NICE TA394 and EoE PAC recommendations | Complete proforma (using agreed local systems) | CCG commission Primary non-familial hypercholesterolaemia or mixed dyslipidaemia. NHSE is responsible commissioner for Homozygous familial hypercholesterolemia |
| Fasinumab | 10 | Inhibits nerve growth factor (NGF). | Osteoarthritis. | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch-2024. Secondary care initiated, primary care continuation. Phase III clinical trial (SPS) April 2020. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Fidaxomicin (Dificlir) | 5.1.8 | Antibacterials | C. difficile associated diarrhoea (CDAD) | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch for granules for oral suspension in 2021 |
| Filgotinib | | JAK inhibitor | Rheumatoid arthritis (RA), moderate-to-severe | NICE TA676 February 2021 | In line with NICE TA676 | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. |
| Filgotinib | | JAK inhibitor | Ulcerative colitis (UC) | NICE ID3736 Proposed GID-TA10600 Publication date | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch 2020. NHS England is responsible commissioner for paediatric use. |
| Filgotinib | | JAK inhibitor | Crohn's disease | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch 2020. NHS England is responsible commissioner for paediatric use. |
| Fluocinolone acetonide intravitreal implant | 11.4.1 | Macular oedema | Chronic diabetic macular oedema after an inadequate response to prior therapy | NICE TA301, November 2013 | In line with NICE TA301. | Complete proforma (using agreed local systems) | |
| Fluocinolone acetonide intravitreal implant | 11.4.1 | Corticosteroid implant | Recurrent non infectious uveitis | NICE TA590 July 2019 | In line with NICE TA590 | Complete proforma (using agreed local systems) | |
| Fluocinolone acetonide intravitreal implant | 11.4.1 | Corticosteroid implant | Chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy | NICE TA613 November 2019 Negative appraisal | NOT COMMISSIONED | NOT COMMISSIONED | |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Fomepizole | | Poisoning | Poisoning | National Poisons Centre Guidelines | Only commissioned in line with National Poison Centres guidelines. | Local Commissioner to be notified / invoiced when used. | |
| Fostamatinib | | Antihemorrhagics, other systemic haemostatics. | Persistent or chronic immune thrombocytopenia | NICE ID1087 Proposed [GID-TA10387] Negative FAD. Expected publication date TBC | NOT COMMISSIONED | NOT COMMISSIONED | |
| Fremanezumab | | Humanised monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP). | Prevention of migraine | NICE TA631 June 2020 | In line with NICE TA631 | Complete proforma (using agreed local systems) | |
| Galcanezumab | 4 | Monoclonal-antibody, calcitonin gene-related peptide antagonist | Prevention of chronic or episodic migraine. | NICE TA659 November 2020 | In line with TA659 | Complete proforma (using agreed local systems) | |
| Galcanezumab | 4 | Monoclonal-antibody, calcitonin gene-related peptide antagonist | Prevention of cluster headache | NICE ID1212 In development [GID-TA10425] - TA suspended | NOT COMMISSIONED | NOT COMMISSIONED | Launch date not known. |
| Golimumab | 10.1.3 | Cytokine modulators | Psoriatic Arthritis | NICE TA220 April 2011 | In line with NICE TA220. | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Golimumab | 10.1.3 | Cytokine modulators | Rheumatoid arthritis | NICE TA225 June 2011 or NICE TA375 January 2016 (partial review of TA375, NICE ID2710. In development [GID-TA10586] Expected publication date: TBC | In line with NICE TA375 or TA225 | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use. |
| Golimumab | 1.5.3 | Cytokine modulators | Moderate to severe ulcerative colitis-second line | NICE TA329 Feb 2015 | In line with NICE TA329 | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use. |
| Golimumab | 10.1.3 | Cytokine modulators | Ankylosing spondylitis | NICE TA383 February 2016 | In line with NICE TA383 | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use. |
| Golimumab | 10.1.3 | Cytokine modulators | Axial spondyloarthritis (non-radiographic) | NICE TA497 January 2018 | In line with NICE TA497 | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use. |
| Guselkumab | 13.5.3 | Drugs affecting the immune response. | Plaque psoriasis, moderate-to-severe | NICE TA521 June 2018 | In line with NICE TA521 | Complete proforma (using agreed local systems) | |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Guselkumab | 13.5.3 | Drugs affecting the immune response. | active psoriatic arthritis after inadequate response to DMARDs | NICE [ID1658] In development [GID-TA10561] Expected publication date: June 2021 | NOT COMMISSIONED | NOT COMMISSIONED | |
| Idarucizumab | 2.8.4 | Oral anticoagulant reversal agents | Reversal agent for dabigatran | | Only in line with Local Policies | Complete proforma (using agreed local systems) | |
| ICES13 injection | 7 | Autologous myoblast cell-based therapy, given by intra-sphincter muscle injection. ATMP. | Stress urinary incontinence – second-line, in women. | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | UK launch plans uncertain |
| Iloprost | 2.5.1 | Vasodilator antihypertensive drugs/Pulmanory Arterial Hypertension | Critical limb ischaemia | No NICE guidance anticipated. | Only in line with Local Policies | NOT COMMISSIONED | NHSE commissioned when used for pulmonary arterial hypertension at specialist centres. |
| Infliximab IV or biosimilar | 1.5.3 | Cytokine modulators | Crohn's Disease | NICE TA187, May 2010 | In line with NICE TA187 | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis,connective tissue, interstital lung disease, graft versus host, renal, sarcoidosis, hidadentis suppurativa and Bechets syndrome. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Infliximab IV or biosimilar | 10.1.3 | Cytokine modulators | Rheumatoid Arthritis | NICE TA195 August 2010 or NICE TA375 January 2016 (partial review of TA375, NICE ID2710. In development [GID-TA10586] Expected publication date: TBC | In line with NICE TA375 or TA195. | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis,connective tissue, interstital lung disease, graft versus host, renal, sarcoidosis, hidadentis suppurativa and Bechets syndrome. |
| Infliximab IV or biosimilar | 10.1.3 | Cytokine modulators | Psoriatic Arthritis | NICE TA199, August 2010 | In line with NICE TA199. | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis,connective tissue, interstital lung disease, graft versus host, renal, sarcoidosis, hidadentis suppurativa and Bechets syndrome. |
| Infliximab or biosimilar | 13.5.3 | Cytokine modulators | Psoriasis (adults) | NICE TA134, January 2008 | In line with NICE TA134. | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis,connective tissue, interstital lung disease, graft versus host, renal, sarcoidosis, hidadentis suppurativa and Bechets syndrome. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Infliximab IV or biosimilar | 1.5.3 | Cytokine modulators | Ulcerative Colitis (acute exacerbations) | NICE TA163, December 2008 | In line with NICE TA163. | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis,connective tissue, interstital lung disease, graft versus host, renal, sarcoidosis, hidadentis suppurativa and Bechets syndrome. |
| Infliximab or biosimilar | 1.5.3 | Cytokine modulators | Ulcerative Colitis - 2nd line for moderate to severely active | NICE TA329 Feb 2015 | In line with NICE TA329 | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis,connective tissue, interstital lung disease, graft versus host, renal, sarcoidosis, hidadentis suppurativa and Bechets syndrome. |
| Infliximab IV or biosimilar | 10.1.3 | Cytokine modulators | Ankylosing spondylitis | NICE TA383 February 2016 | If treatment is started with the least expensive infliximab product in line with NICE TA383 | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis,connective tissue, interstital lung disease, graft versus host, renal, sarcoidosis, hidadentis suppurativa and Bechets syndrome. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Infliximab IV or biosimilar | 10.1.3 | Cytokine modulators | Diarrhoea or colitis associated with Immune Checkpoint Inhibitor (unlicensed indication) | Local policy (PAC statement) | Only in line with Local Policies (PAC policy) | Complete proforma (using agreed local systems) | GP prescribing NOT expected.PAC recommendations published July 2019. NHS England are the responsible commissioner for use in paediatrics. |
| Infliximab IV or biosimilar | 10.1.3 | Cytokine modulators | JIA (unlicensed indication) | Patient currently responding to treatment. | Continuation and discontinuation in line with NHSE policy E03/P/d (EO3X04). No initiation in adults | Complete proforma (using agreed local systems) | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis,connective tissue, interstital lung disease, graft versus host, renal, sarcoidosis, hidadentis suppurativa and Bechets syndrome. |
| Infliximab subcutaenous injection | 13.5.3 | Drugs affecting the immune response | Subcutaenous injection. Licensed indications - gastroenterologic and rheumatologic conditions. | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | |
| Infliximab IV or biosimilar | 10.1.3 | Cytokine modulators | Axial spondyloarthritis (non- radiographic). Unlicensed indication. | Not considered in NICE TA383 February 2016. | NOT COMMISSIONED | NOT COMMISSIONED | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis,connective tissue, interstital lung disease, graft versus host, renal, sarcoidosis, hidadentis suppurativa and Bechets syndrome. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Infliximab IV or biosimilar | 1.5.3 | Cytokine modulators | Ulcerative Colitis (Sub acute manifestations) | NICE TA329 Feb 2015 Not recommended | NOT COMMISSIONED | NOT COMMISSIONED | CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis,connective tissue, interstital lung disease, graft versus host, renal, sarcoidosis, hidadentis suppurativa and Bechets syndrome. |
| Ixekizumab | 13.4.2 | Humanized anti–interleukin-17 monoclonal antibody | Plaque psoriasis | NICE TA442 April 2017 | In line with NICE TA329 | Complete proforma (using agreed local systems) | Adults only, GP prescribing NOT expected. |
| Ixekizumab | 10.1.3 | Humanized anti–interleukin-17 monoclonal antibody | Psoriatic arthritis | NICE TA537 August 2018 | In line with NICE TA537 | Complete proforma (using agreed local systems) | Adults only, GP prescribing NOT expected. |
| Ixekizumab | 10.1.3 | Humanized anti–interleukin-17 monoclonal antibody | Radiographic and non-radiographic axial spondyloarthritis, after NSAIDs | NICE [ID1532] In development [GID-TA10458] Expected publication date: July 2021 | NOT COMMISSIONED | NOT COMMISSIONED | |
| Lanreotide | 8.3.4.3 | Somatostatin Analogues | Non cancer indications. | No NICE guidance anticipated. | Only in line with Local Policies | NOT COMMISSIONED | NHS England is respnsible commissioner for cancer indications and congenital hyperinsulinism and for acromegaly but only when prescribed in a specialist centre. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Levofloxacin Solution for Inhalation | 5.1.2 | Antibacterial drugs | Chronic pulmonary infections due to Pseudomonas aeruginosa in adults with CF | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Only excluded when given by nebulisation/inhalation NHSE commissioning responsibility. From specialist centres only. NHS England policy 170078P August 2018. No GP prescribing. |
| Liothyronine injection | | Other endocrine drugs | Myxoedema coma | No NICE guidance anticipated | In line with PAC recommendations. | NOT COMMISSIONED | |
| Liothyronine injection | | Other endocrine drugs | Thyroid replacement in patients who are long term nil by mouth. | No NICE guidance anticipated | In line with PAC recommendations. | NOT COMMISSIONED | Unlicensed indication. |
| Liothyronine injection | | Other endocrine drugs | Management of organ donor patients post brain death. | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | Unlicensed indication. |
| Lusutrombopag | | Platelet Disorder Drugs | Thrombocytopenia in adults with chronic liver disease prior to elective procedures | NICE TA 617, January 2020 | In line with NICE TA617 | Complete proforma (using agreed local systems) | |
| Macimorelin (oral) | | Growth Hormone | Growth hormone deficiency in adults | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | UK launch plans unceratin |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Mannitol | 3.7 | Mucolytics | Cystic Fibrosis | NICE TA266 November 2012 | NHSE Policy -Inhaled Therapy For Adults And Children With Cystic Fibrosis Policy Ref: A01/P/b Dec 2014. GPs prescribe for patients subject to local commissioner agreement. | NHSE responsibility | NHSE. Only excluded when given by nebulisation / inhalation. |
| Mannitol | 3.7 | Mucolytics | Indications other than cystic fibrosis. | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | |
| Masitinib | | Protein tyrosine kinase inhibitor | Moderate Crohn's disease in patients intolerant or with an unsatisfactory response to, immunosuppressive drugs and/or TNF-inhibitors | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch not known. NHSE responsible commisisoner for cancer indications/GIST. NHSE anticipated to be responsible commissioner for severe asthma and MS indications. |
| Masitinib | | Protein tyrosine kinase inhibitor | Mild to moderate Alzheimer's disease - adjunct | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch 2022. NHSE responsible commisisoner for cancer indications/GIST. NHSE anticipated to be responsible commissioner for severe asthma and MS indications. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Masitinib | | Protein tyrosine kinase inhibitor | Amyotrophic Lateral Sclerosis (ALS) | NICE (ID967) [GID-TA10157] Suspended | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch 2022. NHSE responsible commisisoner for cancer indications/GIST. NHSE anticipated to be responsible commissioner for severe asthma and MS indications. |
| Mavrilimumab | | | Rheumatoid arthritis | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | |
| Mepolizumab | | Fully humanised IgG monoclonal antibody specific for interleukin 5 | Chronic obstructive pulmonary disease | NICE (ID1237) Proposed [GID-TA10239] Expected publication date: TBC | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2022. NHS England responsible commissioner for asthma indication.Eosinophilic Granulomatosis with Polyangiitis (Churg Strauss syndrome) - NHSE likely to be responsible commissioners. |
| Mepolizumab | | Fully humanised IgG monoclonal antibody specific for interleukin 5 | Previously treated severe chronic rhinosinusitis with nasal polyps | NICE (ID3817) Proposed [GID-TA10701] Expected publication date: July 2022 | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2022. NHS England responsible commissioner for asthma indication.Eosinophilic Granulomatosis with Polyangiitis (Churg Strauss syndrome) - NHSE likely to be responsible commissioners. |
| Nemolizumab | | IL-31 RA monoclonal antibody | moderate to severe atopic dermatitis | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2022. Not on excluded drugs list currently |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Nemolizumab | | IL-31 RA monoclonal antibody | Moderate to severe prurigo nodularis | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2022. Not on excluded drugs list currently |
| Mirikizumab | | IgG4 humanised monocloncal antibody | Moderate to severe plaque psoriasis | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2021. Not on excluded drugs list currently |
| Mirikizumab | | IgG4 humanised monocloncal antibody | Moderately to severely active Crohn's disease | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2023. Not on excluded drugs list currently |
| Mirikizumab | | IgG4 humanised monocloncal antibody | Moderate-to-severe active ulcerative colitis | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2023. Not on excluded drugs list currently |
| Nitazoxanide | | Thiazolide (first-in-class). | Treatment of acute uncomplicated influenza virus infections. | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | NHS England responsible commissioner for Hepatitis C. |
| Ocriplasmin | 11.8.2 | Retinal disorders | Vitreomacular traction including those associated with macular holes. | NICE TA297 Oct 2013 | In line with NICE TA297 | Complete proforma (using agreed local systems) | GP prescribing NOT recommended. |
| Octreotide | 8.3.4.3 | Somatostatin Analogues | Non cancer indications | | Only in line with Local Policies | Complete proforma (using agreed local systems) | NHS England responsible commissioner for cancer, congenital hyperinsulinaemia and acromegaly but only when prescribed in a specialist centre. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Olokizumab | | Cytokine modulator | Moderate-to-severe rheumatoid arthritis in adults who previously failed DMARD therapy | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date uncertain |
| Omalizumab | 3.4.2 | Allergen Immunotherapy | Previously treated chronic spontaneous urticaria | NICE TA339 June 2015 | In line with NICE TA339 | Complete proforma (using agreed local systems) | NHS England responsible for asthma & chronic sinusitis with nasal polyps indication |
| Omalizumab | 3.4.3 | Allergen Immunotherapy | Food allergy - in patients with multiple food allergies | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch 2022 |
| Ozanimod | 8.2 | Selective sphingosine 1-phosphate 1 receptor (S1P1R) modulator | moderate to severe ulcerative colitis | NICE [ID3841] In development [GID-TA10732] Date: TBC | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch 2021 |
| Ozanimod | 8.2 | Selective sphingosine 1-phosphate 1 receptor (S1P1R) modulator | Moderate-to-severe active Crohn's disease | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch 2023 |
| Pegaptanib | 11.8.2 | Subfoveal choroidal neovascularisation | Neovascular (wet) age-related macular degeneration | NICE guideline [NG82] not recommended | NOT COMMISSIONED | NOT COMMISSIONED | |
| Peginterferon alfa-2a | 8.4.2 | Other immunomodulating drugs | Myeoprolific disorders: Polycythaemia Vera (PV) and Essential Thrombocythaemia (ET) | No NICE guidance anticipated. | Only in line with Local Policies | NOT COMMISSIONED | NHS England responsible commissioner for cancer, congenital hyperinsulinaemia and acromegaly but only when prescribed in a specialist centre.NHS England is responsible commissioner for Hepatitis B and C. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Phenylephrine with Ketorolac | 11.4.02 | Retinal disorders / intraocular lens replacement surgery | Intraocular lense replacement surgery | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Licensed but not launched. |
| Piclidenoson | | Adenosine A3 receptor agonist | Rheumatoid arthritis - first-line | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch 2021 |
| Piclidenoson | | Adenosine A3 receptor agonist | Plaque psoriasis, moderate-to-severe. | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch 2022 |
| Pitolisant | 4.1.1 | Hypnotics and anxiolytics | Excessive daytime sleepiness caused by obstructive sleep apnoea | NICE ID1065. Proposed [GID-TA10385] Expected publication date: TBC | NOT COMMISSIONED | NOT COMMISSIONED | |
| Pitolisant | 4.1.1 | Hypnotics and anxiolytics | Narcolepsy with or without cataplexy | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | |
| Ranibizumab or biosimilar | 11.8.2 | Neovascularisation | Neovascular (wet) age-related macular degeneration | NICE TA155, August 2008 | In line with NICE TA155. | Complete proforma (using agreed local systems) | GP prescribing NOT expected. Biosimilar predicted UK launch 2022 |
| Ranibizumab or biosimilar | 11.8.2 | Neovascularisation | Diabetic Macular Oedema | NICE TA274, Feb 2013 | In line with TA274. | Complete proforma (using agreed local systems) | GP prescribing NOT expected. Biosimilar predicted UK launch 2022 |
| Ranibizumab or biosimilar | 11.8.2 | Neovascularisation | Macular oedema (retinal vein occlusion) | NICE TA283, May 2013 | In line with TA283. | Complete proforma (using agreed local systems) | GP prescribing NOT expected. Biosimilar predicted UK launch 2022 |
| Ranibizumab or biosimilar | 11.8.2 | Neovascularisation | CNV due to pathological myopia | NICE TA298, November 2013 | In line with TA298. | Complete proforma (using agreed local systems) | GP prescribing NOT expected. Biosimilar predicted UK launch 2022 |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Ranibizumab or biosimilar | 11.8.2 | Neovascularisation | Visual impairment due to choroidal neovascularisation (CNV) other than due to wet age-related macular degeneration, or pathologic myopia. | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Biosimilar predicted UK launch 2022 |
| Ranibizumab or biosimilar | 11.8.3 | Neovascularisation | Moderately-severe to severe non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) 2019 | NICE TA637 June 2020 Terminated appraisal | NOT COMMISSIONED | NOT COMMISSIONED | Biosimilar predicted UK launch 2022 |
| Reltecimod | | Immunomodulating drugs | necrotising soft tissue infection | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date uncertain |
| Remestemcel-L | | Human mesenchymal stem cells given by i.v. infusion in four visits over two weeks. This is an ATMP. | Crohn's disease, moderate-to-severe, in patients who have previously failed at least one steroid, and at least one immunomodulator or biologic. | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date uncertain |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Rexmyelocel-T | | Autologous bone marrow-derived mononuclear cells, which promote angiogenesis. ATMP. | Critical limb ischaemia. | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date uncertain |
| Rintatolimod | 4 | Immunomodulating drugs | Chronic fatigue syndrome | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date uncertain |
| Risankizumab | | Humanised IgG1 Monoclonal antibody | Chronic plaque psoriasis moderate-severe | NICE TA 596 August 2019 | In line with NICE TA 596 | Complete proforma (using agreed local systems) | Adults only, GP prescribing NOT expected. |
| Risankizumab | | Humanised IgG1 Monoclonal antibody | Psoriatic arthritis | NICE ID1399. Proposed [GID-TA10819] Expected publication date: TBC . | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2021. It is anticipated that NHSE is responsible commissioner for paediatric use. |
| Risankizumab | | Humanised IgG1 Monoclonal antibody | Crohn's disease | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2022. It is anticipated that NHSE is responsible commissioner for paediatric use. |
| Risankizumab | | Humanised IgG1 Monoclonal antibody | Ulcerative colitis | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2024. It is anticipated that NHSE is responsible commissioner for paediatric use. |
| Rituximab or biosimilar | 10.1.3 | Cytokine modulators | Rheumatoid Arthritis after failure of TNF inhibitor | NICE TA195, Aug 2010 | In line with NICE TA195. | Complete proforma (using agreed local systems) | NHS England are the responsible responsible commissioner for indications listed on the Indications for NHS England drug list https://www.england.nhs.uk/publication/nhs-england-drugs-list/ |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Rituximab or biosimilar | 10.1.3 | Cytokine modulators | Rheumatoid arthritis (first line) (unlicensed indication) | No NICE guidance anticipated. | Only in line with Local Policies | Complete proforma (using agreed local systems) | NHS England are the responsible responsible commissioner for indications listed on the Indications for NHS England drug list https://www.england.nhs.uk/publication/nhs-england-drugs-list/ |
| Rituximab or biosimilar | 10.1.3 | Cytokine modulators | ITP (unlicensed indication) | No NICE guidance anticipated. | Only in line with Local Policies | Complete proforma (using agreed local systems) | NHS England are the responsible responsible commissioner for indications listed on the Indications for NHS England drug list https://www.england.nhs.uk/publication/nhs-england-drugs-list/ |
| Rituximab or biosimilar | 10.1.3 | Cytokine modulators | Refractory vasculitis (unlicensed indication) | | Only in line with Local Policies | NOT COMMISSIONED | NHS England are the responsible responsible commissioner for indications listed on the Indications for NHS England drug list https://www.england.nhs.uk/publication/nhs-england-drugs-list/ |
| Rituximab or biosimilar | 10.1.3 | Cytokine modulators | JIA (unlicensed indication) | Patient currently responding to treatment,transitioned from the NHS England paediatric service | Continuation and discontinuation in line with NHSE policy E03/P/d (EO3X04). No initiation in adults | Complete proforma (using agreed local systems) | NHS England are the responsible responsible commissioner for indications listed on the Indications for NHS England drug list https://www.england.nhs.uk/publication/nhs-england-drugs-list/ |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Romiplostim | 9.1.4 | Platelet Disorder Drugs | ITP | NICE TA221 April 2011 | In line with NICE TA221. | Complete proforma (using agreed local systems) | GP prescribing NOT expected. Local Commissioner. NHSE responsible commissioner for paediatric ITP. |
| Romosozumab | | Humanised monoclonal antibody, sclerostin inhibitor | Osteoporosis in men and postmenopausal women | Non-bisphosphonates for treating osteoporosis NICE [ID901] In development [GID-TA10072] Expected publication—TBC | NOT COMMISSIONED | NOT COMMISSIONED | UK launch March 2020. It is anticipated that NHSE is responsible commissioner for use in men. |
| Romosozumab | | Humanised monoclonal antibody, sclerostin inhibito | Osteoporosis in men and postmenopausal women | Severe osteoporosis NICE ID3936 Proposed [GID-TA10828]Expected publication date: TBC | NOT COMMISSIONED | NOT COMMISSIONED | |
| Ruxolitinib | | JAK inhibitor | Polycythaemia vera | NICE TA356 September 2015 Terminated appraisal | NOT COMMISSIONED | NOT COMMISSIONED | UK availability 2021. NHSE are responsible commissioners for cancer indication. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Ruxolitinib | | JAK inhibitor | Chronic graft versus host disease (GvHD) | NICE [ID2716] In development [GID-TA10761] Date: TBC- (Currently suspended) | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch 2021. NHSE are responsible commissioners for cancer indication and Acute graft versus host disease (GvHD). |
| Ruxolitinib | | JAK inhibitor | Alopecia areata, moderate-to-severe | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch 2023. NHSE are responsible commissioners for cancer indication and Acute graft versus host disease (GvHD). |
| Ruxolitinib | | JAK inhibitor | Atopic dermatitis | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2021 or 2022 ( uncertain). NHSE are responsible commissioners for cancer indication and Acute graft versus host disease (GvHD). |
| Sarilumab | No BNF category | Cytokine modulators | Moderately to severely active rheumatoid arthritis (RA) second line to DMARDs. | NICE TA485 November 2017 | In line with NICE TA485. | Complete proforma (using agreed local systems) | Adults only. GP prescribing NOT expected. NHS England responsible commissioner for paediatric use but do not commission as unlicensed indication. |
| Secukinumab | 10.1.3 | Cytokine modulators | Chronic plaque psoriasis moderate-severe after failed conventional therapies | NICE TA350 July 2015 | In line with NICE TA350 | Complete proforma (using agreed local systems) | Adults only. GP prescribing NOT expected. NHS England responsible commissioner for paediatric use but do not commission as unlicensed indication. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Secukinumab | 10.1.3 | Cytokine modulators | Ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors | NICE TA407 September 2016 | In line with NICE TA407 | Complete proforma (using agreed local systems) | Adults only. GP prescribing NOT expected. NHS England responsible commissioner for paediatric use but do not commission as unlicensed indication. |
| Secukinumab | | Cytokine modulators | Psoriatic arthritis, second line | NICE TA455 May 2017 | In line with NICE TA407 | Complete proforma (using agreed local systems) | Adults only. GP prescribing NOT expected. NHS England responsible commissioner for paediatric use but do not commission as unlicensed indication. |
| Secukinumab | 10.1.3 | Cytokine modulators | Axial - spondyloarthritis (non-radiographical) | NICE [ID1419] Proposed [GID-TA10457] Publication date July 2021 | NOT COMMISSIONED | NOT COMMISSIONED | |
| Secukinumab | 10.1.3 | Cytokine modulators | Psoriatic arthritis, axial manifestations | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | |
| Sirolimus (invitreal) | | | chronic non-infectious, posterior segment uveitis | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2022 |
| Sodium oxybate | 4.1 | Hypnotics and anxiolytics | Narcolepsy with cataplexy (adults) | No NICE guidance anticipated. | EoE PAC policy | NOT COMMISSIONED | NHS England is responsible commissioner for paediatric use. |
| Solriamfetol | | Hypnotics and anxiolytics | Excessive daytime sleepiness caused by obstructive sleep apnoea | ID[1499] Proposed [GID-TA10430] Publication date TBC | NOT COMMISSIONED | NOT COMMISSIONED | |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Solriamfetol | 4.1 | Hypnotics and anxiolytics | Excessive waketime sleepiness caused by narcolepsy | ID[1602] Proposed [GID-TA10524] Publication date TBC | NOT COMMISSIONED | NOT COMMISSIONED | |
| Somapacitan | 6.5.1 | Growth Hormone & growth hormone Receptor Antagonist. Long acting. | Growth hormone deficiency in adults and pre-pubertal children | No NICE guidance expected. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2021 for adults and 2022 fpr pre- pubertal children. NHS England is responsible commissioner for paediatric use. |
| Somatrogon | 6.5.3 | Growth Hormone & growth hormone Receptor Antagonist. Long-acting formulation of somatotropin. | Growth hormone deficiency in adults. | No NICE guidance expected. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2021. NHS England is responsible commissioner for paediatric use. |
| Somatropin (adults) | 6.5.1 | Growth Hormone or Growth Hormone Receptor Antagonist | Adults with growth hormone deficiency | NICE TA64 August 2013 | In line with NICE TA64 | Complete proforma (using agreed local systems) | Local Commissioner |
| Somatropin (children) | 6.5.1 | Growth Hormone or Growth Hormone Receptor Antagonist | Growth failure in children | NICE TA188, May 2010 | In line with NICE TA188 and EoE PAC recommendations | Complete proforma (using agreed local systems) | Local Commissioner and GOSH NB: Shared care arrangements with GPs in place. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Tanezumab | 4.7 | Nerve growth factor inhibitor | Osteoarthritis | NICE [ID1603] Proposed [GID-TA10711] Expected publication date September 2021 | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch-2021 |
| Tanezumab | 4.7 | Nerve growth factor inhibitor | Chronic low back pain | No NICE guidance expected. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch uncertain |
| Tanezumab | 4.7 | Nerve growth factor inhibitor | Cancer pain due to bone metastasis in adults already taking background opioid therapy | No NICE guidance expected. | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch-2022 |
| Teriparatide or biosimilar | 6.6.1 | Drugs affecting bone metabolism | Secondary prevention of osteoporotic fragility fractures in postmenopausal women. | NICE TA161 Jan 2011. Note: NICE review Non-bisphosphonates for treating osteoporosis [ID901] In development [GID-TA10072] May 2021 | In line with NICE TA161 guidance or locally agreed protocols. | Complete proforma (using agreed local systems) | GP prescribing NOT expected. Local Commissioner. NHSE responsible commissioner for male and juvenile osteoporosis. |
| Teriparatide or biosimilar | 6.6.1 | Drugs affecting bone metabolism | Treatment of osteoporosis associated with glucocorticoids | NICE review Non-bisphosphonates for treating osteoporosis [ID901] In development [GID-TA10072] May 2021 | NOT COMMISSIONED | NOT COMMISSIONED | |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Thrombomodulin Recombinant Human | 2 | Fibrinolytic. Recombinant human thrombomodulin | Septic shock (Sepsis) - with disseminated intravascular coagulation (DIC) | No NICE guidance anticipated. | NOT COMMISSIONED | NOT COMMISSIONED | NHSE responsible commissioner for pseudoanerysm. Predicted UK launch uncertain |
| Tildrakizumab | 13 | Human interleukin-23 antagonist | Plaque psoriasis in adults, moderate-to-severe | NICE TA575 April 2019 | In line with NICE TA575 | Complete proforma (using agreed local systems) | |
| Tobramycin (Tobi®/Bramitob®) nebuliser solution | 5.1.4 | Antibacterial Drugs | Cystic Fibrosis | | NHSE Policy -Inhaled Therapy For Adults And Children With Cystic Fibrosis Policy Ref: A01/P/b Dec 2014 | NHSE responsibility. No GP prescribing. | Only excluded when given by nebulisation / inhalation. |
| Tobramycin (Tobi® Podhaler) dry powder for inhalation | 5.1.5 | Antibacterial Drugs | Cystic Fibrosis | NICE TA276 March 2013 | NHSE Policy -Inhaled Therapy For Adults And Children With Cystic Fibrosis Policy Ref: A01/P/b Dec 2014 | No GP prescribing as Patient Access Scheme not available in primary care. | Only excluded when given by nebulisation / inhalation. |
| Tocilizumab | 10.1.3 | Cytokine modulator | Rheumatoid Arthritis | NICE TA247 Feb 2012 or NICE TA375 January 2016. (partial review of TA375, NICE ID2710. In development [GID-TA10586] Expected publication date: TBC | In line with NICE TA247 or TA375 | Complete proforma (using agreed local systems) | Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, paediatric juvenile arthritis (NICE TA 373 and TA238) Takayasu arteritis and Giant cell arteritis (NICE TA518), systemic sclerosis and COVID-19 severe pneumonia.. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Tocilizumab | 10.1.3 | Cytokine modulators | Polyarticular juvenile idiopathic arthritis | NICE TA373 Dec 2015 | In line with NICE TA373 criteria and continuation in young adults tranisitioning from NHS England paeds service | Complete proforma (using agreed local systems) | Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, paediatric juvenile arthritis (NICE TA 373 and TA238) Takayasu arteritis and Giant cell arteritis, systemic sclerosis and COVID-19 severe pneumonia. |
| Tofacitinib | 10.3.1 | Cytokine modulator | Rheumatoid arthritis, moderate-to-severe, in patients not responding to DMARDs or methotrexate. | NICE TA480 October 2017 | In line with NICE TA480 | Complete proforma (using agreed local systems) | It is anticipated that NHSE is responsible commissioner for paediatric use. |
| Tofacitinib | 10.3.1 | Cytokine modulator | Psoriatic arthritis second-line following failure of conventional DMARDs, third-line following failure of biological DMARDs | NICE TA543 October 2018 | In line with NICE TA543 | Complete proforma (using agreed local systems) | It is anticipated that NHSE is responsible commissioner for paediatric use. |
| Tofacitinib | 10.3.1 | Cytokine modulator | Moderate-to-severe active ulcerative colitis in adults, following failure of conventional therapy. | NICE TA547 November 2018 | In line with NICE TA547 | Complete proforma (using agreed local systems) | It is anticipated that NHSE is responsible commissioner for paediatric use. |
| Tofacitinib | 10.3.1 | Cytokine modulator | Ankylosing spondylitis | NICE ID[3865] Proposed [GID-TA10771] Publication date TBC | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2021 |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Tofacitinib | 10.3.1 | Cytokine modulator | JIA | NICE ID[2718] Proposed [GID-TA10706] Publication date October 2021 | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2021. It is anticipated that NHSE is responsible commissioner for paediatric use. |
| Tolvaptan | 6.5.2 | Vasopressin V2-receptor antagonist | Autosomal dominant polycystic kidney disease, stage 2 or 3, rapidly progressing | NICE TA358 October 2015 | In line with NICE TA358. | Complete proforma (using agreed local systems) | NHSE responsible for commissioning in hyponatraemia in cancer patients requiring chemotherapy. |
| Tolvaptan | 6.5.2 | Vasopressin V2-receptor antagonist | Hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) in patients who do not require chemotherapy. | No NICE guidance anticipated. | In line with PAC recommendations. | NOT COMMISSIONED | NHSE responsible for commissioning in hyponatraemia in cancer patients requiring chemotherapy. |
| Tolvaptan | 6.5.2 | Vasopressin V2-receptor antagonist | Hyponatraemia from other causes and other endocrine uses | No NICE guidance anticipated. | Only in line with Local Policies | NOT COMMISSIONED | NHSE responsible for commissioning in hyponatraemia in cancer patients requiring chemotherapy. |
| Tralokinumab | | Monoclonal antibody | Moderate to severe atopic dermatitis | NICE ID3734 Proposed [GID-TA10596] Expected publication December 2021 | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2021. It is anticipated that NHSE is responsible commissioner for paediatric use. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Upadacitinib | 10 | Janus kinase (JAK) inhibitor | Severe rheumatoid arthritis | NICE TA665 December 2020 | In line with NICE TA665 | Complete proforma (using agreed local systems) | It is anticipated that NHSE is responsible commissioner for paediatric use and Giant cell (temporal) arteritis. |
| Upadacitinib | 10 | Janus kinase (JAK) inhibitor | Previously treated moderate active rheumatoid arthritis | NICE ID3878 Proposed [GID-TA10759] Expected publication date: TBC | NOT COMMISSIONED | NOT COMMISSIONED | It is anticipated that NHSE is responsible commissioner for paediatric use and Giant cell (temporal) arteritis. |
| Upadacitinib | 10 | Janus kinase (JAK) inhibitor | Ulcerative colitis (UC) | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2023. It is anticipated that NHSE is responsible commissioner for paediatric use and Giant cell (temporal) arteritis. |
| Upadacitinib | 10 | Janus kinase (JAK) inhibitor | Crohn's disease | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2023. It is anticipated that NHSE is responsible commissioner for paediatric use and Giant cell (temporal) arteritis. |
| Upadacitinib | 10 | Janus kinase (JAK) inhibitor | Active psoriatic arthritis after inadequate response to DMARDs | NICE ID2690 Proposed [GID-TA10666] Expected publication date: Aug 2021 | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2021. It is anticipated that NHSE is responsible commissioner for paediatric use and Giant cell (temporal) arteritis. |
| Upadacitinib | 10 | Janus kinase (JAK) inhibitor | active ankylosing spondylitis | NICE ID3848 Proposed [GID-TA10735] Expected publication date: TBC | NOT COMMISSIONED | NOT COMMISSIONED | Launch date 2021. It is anticipated that NHSE is responsible commissioner for paediatric use and Giant cell (temporal) arteritis. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Upadacitinib | 10 | Janus kinase (JAK) inhibitor | Axial spondyloarthritis | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | Launch date 2023. It is anticipated that NHSE is responsible commissioner for paediatric use and Giant cell (temporal) arteritis. |
| Upadacitinib | 10 | Janus kinase (JAK) inhibitor | Moderate-to-severe atopic dermatitis | NICE ID3733 Proposed [GID-TA10597] Expected publication date: October 2021 | NOT COMMISSIONED | NOT COMMISSIONED | UK launch 2021. It is anticipated that NHSE is responsible commissioner for paediatric use and Giant cell (temporal) arteritis. |
| Ustekinumab | 13.5.3 | Drugs affecting the immune response | Psoriasis moderate to severe | NICE TA180, Sept 2009 | In line with NICE TA180. | Complete proforma (using agreed local systems) | Adults only. GP prescribing NOT expected. NHSE is responsible commissioner for NICE TA455 for paediatric indications of adult TAs. |
| Ustekinumab | 10.1.3 | Drugs affecting the immune response | Psoriatic arthritis | NICE TA340 June 2015 | In line with NICE TA340 | Complete proforma (using agreed local systems) | Adults only. GP prescribing NOT expected. NHSE is responsible commissioner for NICE TA455 for paediatric indications of adult TAs. |
| Ustekinumab | 1.5.3 | Drugs affecting the immune response | Ustekinumab for moderately to severely active Crohn's disease after previous treatment | TA456 July 2017 | In line with NICE TA456. | Complete proforma (using agreed local systems) | Adults only. GP prescribing NOT expected. NHSE is responsible commissioner for NICE TA455 for paediatric indications of adult TAs. |
| Ustekinumab | 13.5.3 | Drugs affecting the immune response | Ulcerative colitis, moderate-to-severe active disease, second-line | NICE TA633 June 2020 | In line with NICE TA633 | Complete proforma (using agreed local systems) | NHSE is responsible commissioner for paediatric indications. |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Vadadustat | 9 | Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor | Anaemia in chronic kidney disease, dialysed and non-dialysed patients - first line | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | Predicted UK launch date 2022. NHS England is responsible commissioner for dialysis induced anaemia. |
| Valbenazine | 4 | Vesicular monoamine transporter-2 inhibitor | Tardive dyskinesia in adults | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | Launch date not known. |
| Vedolizumab IV | 1.5.3 | Drugs affecting the immune response | Moderate to severe ulcerative colitis - second line after conventional therapy or TNF inhibitor | NICE TA342 June 2015 | In line with NICE TA342 and locally agreed patient pathway | Complete proforma (using agreed local systems) | NHS England is responsible commissioner for paediatric use. GP prescribing NOT expected. |
| Vedolizumab IV | 1.5.3 | Drugs affecting the immune response | Crohn's disease second line after conventional therapy and TNF inhibitors | NICE TA352 Aug 2015 | In line with NICE TA352 | Complete proforma (using agreed local systems) | NHS England is responsible commissioner for paediatric use. GP prescribing NOT expected. |
| Vedolizumab Sub cut | 13.5.3 | Drugs affecting the immune response | Ulcerative colitis and Crohn’s disease. | No NICE guidance anticipated | Only in line with Local Policies | Complete proforma (using agreed local systems) | NHS England is responsible commissioner for paediatric use |
| Vericiguat (oral) | | Soluble guanylate cyclase stimulator | Chronic heart failure with reduced ejection fraction | NICE ID2731 Proposed [GID-TA10595] Expected publication date: TBC | NOT COMMISSIONED | NOT COMMISSIONED | UK availability 2021 |

**Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs and devices 2021/2022**

| Drug name | BNF section | Category | Licensed Indication/ Indication | NICE Guidance | Indications agreed for funding across EoE | Is this commissioned? What is required for funding approval? | Notes |
|---|---|---|---|---|---|---|---|
| Verteporfin | 11.8.2 | Subfoveal choroidal neovascularisation | Photodynamic therapy for wet age-related degeneration. | NICE guideline [NG82] Jan 2018 (replaces NICE TA68, September 2003) | Only in line with Local Policies | NOT COMMISSIONED | No GP prescribing. Local Commissioner. |
| Verteporfin | 11.8.2 | Subfoveal choroidal neovascularisation | Photodynamic therapy (PDT) with verteporfin for Chronic Central Serous Retinopathy | No NICE guidance anticipated | NOT COMMISSIONED | NOT COMMISSIONED | |